Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
31089 | 158 | 41.0 | 75% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
21 | 4 | UROLOGY & NEPHROLOGY//UROL//JOURNAL OF UROLOGY | 229838 |
272 | 3 | PROSTATE CANCER//PROSTATIC NEOPLASMS//UROL | 43768 |
534 | 2 | ANDROGEN RECEPTOR//PROSTATE CANCER//CASTRATION RESISTANT PROSTATE CANCER | 14838 |
31089 | 1 | OSTEOBLASTIC METASTASIS//HUMAN BONE MARROW ENDOTHELIAL CELLS//CATTEDRA PATOL GEN | 158 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | OSTEOBLASTIC METASTASIS | authKW | 562209 | 5% | 36% | 8 |
2 | HUMAN BONE MARROW ENDOTHELIAL CELLS | authKW | 289891 | 2% | 50% | 3 |
3 | CATTEDRA PATOL GEN | address | 257678 | 3% | 33% | 4 |
4 | 1 A 25 DIHYDROXY VITAMIN D3 | authKW | 193263 | 1% | 100% | 1 |
5 | ALPHA 2 BETA 1 INTEGRINS | authKW | 193263 | 1% | 100% | 1 |
6 | ANDROGEN ABLATION REFRACTORY | authKW | 193263 | 1% | 100% | 1 |
7 | ANTI APOPTOTIC SIGNALING PATHWAYS | authKW | 193263 | 1% | 100% | 1 |
8 | ANTISURVIVAL FACTOR THERAPY | authKW | 193263 | 1% | 100% | 1 |
9 | BIOL NANOSCI ADV MED | address | 193263 | 1% | 100% | 1 |
10 | BIOMAT QUEBEC EO178 | address | 193263 | 1% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 1182 | 45% | 0% | 71 |
2 | Urology & Nephrology | 400 | 15% | 0% | 24 |
3 | Endocrinology & Metabolism | 280 | 17% | 0% | 27 |
4 | Medicine, General & Internal | 94 | 13% | 0% | 20 |
5 | Cell Biology | 29 | 9% | 0% | 14 |
6 | Medicine, Research & Experimental | 17 | 5% | 0% | 8 |
7 | Biochemistry & Molecular Biology | 3 | 9% | 0% | 14 |
8 | Pharmacology & Pharmacy | 2 | 5% | 0% | 8 |
9 | Anatomy & Morphology | 2 | 1% | 0% | 1 |
10 | Materials Science, Biomaterials | 1 | 1% | 0% | 1 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | CATTEDRA PATOL GEN | 257678 | 3% | 33% | 4 |
2 | BIOL NANOSCI ADV MED | 193263 | 1% | 100% | 1 |
3 | BIOMAT QUEBEC EO178 | 193263 | 1% | 100% | 1 |
4 | BRACHYTHER Y UROL | 193263 | 1% | 100% | 1 |
5 | EXPT PSYSIOL | 193263 | 1% | 100% | 1 |
6 | FDN PUBL INSURANCE | 193263 | 1% | 100% | 1 |
7 | FDN SOCIAL INSURANCE GREECE | 193263 | 1% | 100% | 1 |
8 | GRP EXPT HAEMATOL | 193263 | 1% | 100% | 1 |
9 | HEMATOL ONCOLUROL | 193263 | 1% | 100% | 1 |
10 | MED ENDOCRINOL ONCOL | 193263 | 1% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PROSTATE | 8340 | 9% | 0% | 14 |
2 | ANTICANCER RESEARCH | 3277 | 11% | 0% | 18 |
3 | CLINICAL & EXPERIMENTAL METASTASIS | 2416 | 3% | 0% | 5 |
4 | MOLECULAR MEDICINE | 1992 | 3% | 0% | 4 |
5 | CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY | 1359 | 1% | 1% | 1 |
6 | INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS | 857 | 1% | 0% | 2 |
7 | NATURE CLINICAL PRACTICE ONCOLOGY | 835 | 1% | 0% | 1 |
8 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | 806 | 2% | 0% | 3 |
9 | CANCER JOURNAL - FRANCE | 793 | 1% | 0% | 1 |
10 | PROSTATE CANCER AND PROSTATIC DISEASES | 714 | 1% | 0% | 2 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | DALEZIS, P , GEROMICHALOS, GD , TRAFALIS, DT , PISSIMISSIS, N , PANAGIOTOPOULOU, D , GALAKTIDOU, G , PAPAGEORGIOU, E , PAPAGEORGIOU, A , DAIFOTI, Z , LYMPERI, M , ET AL (2012) DEXAMETHASONE PLUS OCTREOTIDE REGIMEN INCREASES ANTICANCER EFFECTS OF DOCETAXEL ON TRAMP-C1 PROSTATE CANCER MODEL.IN VIVO. VOL. 26. ISSUE 1. P. 75-86 | 27 | 46% | 3 |
2 | PAPAGEORGIOU, E , PITULIS, N , MANOUSSAKIS, M , LEMBESSIS, P , KOUTSILIERIS, M , (2008) ROSIGLITAZONE ATTENUATES INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR SURVIVAL SIGNALING IN PC-3 CELLS.MOLECULAR MEDICINE. VOL. 14. ISSUE 7-8. P. 403-411 | 25 | 52% | 19 |
3 | MSAOUEL, P , PISSIMISSIS, N , HALAPAS, A , KOUTSILIERIS, M , (2008) MECHANISMS OF BONE METASTASIS IN PROSTATE CANCER: CLINICAL IMPLICATIONS.BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM. VOL. 22. ISSUE 2. P. 341-355 | 29 | 41% | 38 |
4 | KOUTSILIERIS, M , MITSIADES, CS , BOGDANOS, J , DIMOPOULOS, T , KARAMANOLAKIS, D , MILATHIANAKIS, C , TSINTAVIS, A , (2004) COMBINATION OF SOMATOSTATIN ANALOG, DEXAMETHASONE, AND STANDARD ANDROGEN ABLATION THERAPY IN STAGE D3 PROSTATE CANCER PATIENTS WITH BONE METASTASES.CLINICAL CANCER RESEARCH. VOL. 10. ISSUE 13. P. 4398-4405 | 22 | 63% | 30 |
5 | PNEUMATICOS, SG , CHRISTOFIDES, A , GKIOKA, E , KALOGEROPOULOS, T , MSAOUEL, P , KOUTSILIERIS, M , (2013) OSTEOPROTEGERIN EXPRESSION DURING THE MICRO- AND MACROMETASTATIC PHASES OF THE OSTEOBLASTIC METASTASIS IN PROSTATE CANCER: THERAPEUTIC IMPLICATIONS.EXPERT OPINION ON THERAPEUTIC TARGETS. VOL. 17. ISSUE 12. P. 1395-1403 | 25 | 45% | 1 |
6 | BOGDANOS, J , KARAMANOLAKIS, D , TENTA, R , TSINTAVIS, A , MILATHIANAKIS, C , MITSIADES, C , KOUTSILIERIS, M , (2003) ENDOCRINE/PARACRINE/AUTOCRINE SURVIVAL FACTOR ACTIVITY OF BONE MICROENVIRONMENT PARTICIPATES IN THE DEVELOPMENT OF ANDROGEN ABLATION AND CHEMOTHERAPY REFRACTORINESS OF PROSTATE CANCER METASTASIS IN SKELETON.ENDOCRINE-RELATED CANCER. VOL. 10. ISSUE 2. P. 279-289 | 29 | 46% | 48 |
7 | MITSIADES, CS , BOGDANOS, J , KARAMANOLAKIS, D , MILATHIANAKIS, C , DIMOPOULOS, T , KOUTSILIERIS, M , (2006) RANDOMIZED CONTROLLED CLINICAL TRIAL OF A COMBINATION OF SOMATOSTATIN ANALOG AND DEXAMETHASONE PLUS ZOLEDRONATE VS. ZOLEDRONATE IN PATIENTS WITH ANDROGEN ABLATION-REFRACTORY PROSTATE CANCER.ANTICANCER RESEARCH. VOL. 26. ISSUE 5B. P. 3693-3700 | 21 | 57% | 19 |
8 | TOULIS, KA , GOULIS, DG , MSAOUEL, P , KOUTSILIERIS, M , (2012) DEXAMETHASONE PLUS SOMATOSTATIN-ANALOG MANIPULATION AS BONE METASTASIS MICROENVIRONMENT-TARGETING THERAPY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A META-ANALYSIS OF UNCONTROLLED STUDIES.ANTICANCER RESEARCH. VOL. 32. ISSUE 8. P. 3283-3289 | 16 | 53% | 4 |
9 | MSAOUEL, P , NANDIKOLLA, G , PNEUMATICOS, SG , KOUTSILIERIS, M , (2013) BONE MICROENVIRONMENT-TARGETED MANIPULATIONS FOR THE TREATMENT OF OSTEOBLASTIC METASTASIS IN CASTRATION-RESISTANT PROSTATE CANCER.EXPERT OPINION ON INVESTIGATIONAL DRUGS. VOL. 22. ISSUE 11. P. 1385 -1400 | 26 | 20% | 2 |
10 | REYES-MORENO, C , SOURLA, A , CHOKI, I , DOILLON, C , KOUTSILIERIS, M , (1998) OSTEOBLAST-DERIVED SURVIVAL FACTORS PROTECT PC-3 HUMAN PROSTATE CANCER CELLS FROM ADRIAMYCIN APOPTOSIS.UROLOGY. VOL. 52. ISSUE 2. P. 341 -347 | 16 | 48% | 26 |
Classes with closest relation at Level 1 |